Health Condition 1: G26- Extrapyramidal and movement disorders in diseases classified elsewhere
Conditions
Interventions
Intervention1: Tetrabenazine: Tetrabenazine will be started in the dose of 12.5 mg twice daily for 1 week followed by 25 mg twice daily for 1 week, followed by 25 mg three times daily
Control Interven
Sponsors
Professor Jayantee Kalita
Eligibility
Inclusion criteria
Inclusion criteria: The patients with newly or already diagnosed Wilson Disease having hyperkinetic disorders dystonia, chorea, tremor.
Exclusion criteria
Exclusion criteria: Patients with head injury, stroke, tumor, malignancy, chronic renal failure, decompensated liver disease, perinatal hypoxia, HIV, organ transplantation, pregnancy and those receiving antipsychotics, corticosteroid, antiemetic and structural brain lesion on MRI not explainable by Wilson Disease will be excluded. Patient with hypokinetic disorders will also be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in BFMDRS, TMC score, TETRAS score by greater than 50% will be considered improved.Timepoint: At baseline and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in neurological severity scale, NPI & DOSS, UWRS, adverse effects. Neurophysiological improvement will be assessed by improvement in H-reflex and blink reflex. The difference in requirement of rescue medications in both the groups will be assessed.Timepoint: After 3 months | — |
Countries
India
Contacts
Public ContactJayantee Kalita
Sanjay Gandhi Post Graduate Institute of medical Sciences
Outcome results
None listed